New EU supply chain to end Visudyne shortage
Monitor the supply chain developments and prepare to adjust inventory management practices as the end of the shortage approaches.
Primary source: Safety monitoring and information
An urgent recall of two batches of Deep Heat Extra Strength 100g cream has been initiated due to contamination.
The urgent recall presents a direct safety risk related to product contamination, necessitating immediate attention from regulatory and safety management teams.
Regulatory Intelligence teams must initiate checks to monitor compliance and management of this recall, ensuring affected lots are removed from distribution.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Regulatory Intelligence teams must initiate checks to monitor compliance and management of this recall, ensuring affected lots are removed from distribution.
An urgent recall has been initiated for two batches of Deep Heat Extra Strength 100g cream in Australia due to contamination concerns, posing a direct safety risk.
What changed: An urgent recall of two batches of Deep Heat Extra Strength 100g cream has been initiated due to contamination.
Why it matters: The urgent recall presents a direct safety risk related to product contamination, necessitating immediate attention from regulatory and safety management teams.
Practical implication: Regulatory Intelligence teams must initiate checks to monitor compliance and management of this recall, ensuring affected lots are removed from distribution.
Published from the regulator source ingestion pipeline after PV impact triage.
Monitor the supply chain developments and prepare to adjust inventory management practices as the end of the shortage approaches.
Monitor for changes in labeling requirements and risk management strategies as a result of the ongoing review by PRAC.
Signal management teams need to prepare for potential updates in labeling, usage guidelines, and monitoring requirements for injectable iron-containing medicines.
Regulatory compliance workflows involving the Dengue Tetravalent Vaccine outside the EU need to incorporate the EMA's positive opinion concerning its use in individuals aged 4 to 60.